游戏里的战斗激情,免费无码毛片一区二区A片小说 ,忍着娇喘人妻被中出中文字幕,中文字幕在线亚洲二区

DiagnoCure  
主要開(kāi)發(fā)創(chuàng)新高附加價(jià)值產(chǎn)品，在細(xì)胞為主的偵測(cè)科技領(lǐng)域和分子診斷試劑領(lǐng)先的廠(chǎng)商，開(kāi)發(fā)應(yīng)用是癌癥早期診斷產(chǎn)品。公司己確定得到PCA3基因的專(zhuān)屬授權(quán)，它是攝護(hù)腺癌高度特異性表現(xiàn)基因。

DiagnoCure (TSX: CUR; OTCQX: DGCRF) is a life sciences corporation that develops and commercializes high-value cancer diagnostic tests that increase clinician and patient confidence in making critical treatment decisions. In 2008, the Corporation launched a colorectal cancer staging test through its U.S. CLIA laboratory. PrevistageTM GCC is currently available for licensing. The Corporation has granted a worldwide exclusive license to Gen-Probe, now a wholly-owned subsidiary of Hologic Inc. (NASDAQ: HOLX) operating as Hologic Gen-Probe, for the development and commercialization of a prostate cancer test using PCA3, DiagnoCure's proprietary molecular biomarker. Hologic Gen-Probe's PROGENSA? PCA3 test is commercialized in Europe under CE mark and is approved for commercialization in Canada and the United States.